Nu-Med Plus swings to Q2 net income of 19,670; operating loss widens to 22,556
Reuters2026/08/14 19:06- Nu-Med Plus posted net income of USD 19,670 for the quarter ended June 30, 2026, returning to profit from a net loss.
- Operating loss widened to USD 22,556, while total operating expenses climbed to USD 22,556.
- Other income was USD 45,000, reflecting a no-shop fee tied to a non-binding letter of intent with Avid Gold.
- Interest expense increased to USD 2,774; the company reported no revenue for the quarter.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
